Clinical trials: Ophthalmic Solutions
Neovascular Age Related Macular Degeneration
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
The purpose of this study is to evaluate the safety and efficacy of topical ophthalmic squalamine lactate eye drops in treating patients with neovascular age-related macular degeneration (wet AMD), a degenerative retinal eye…
- Trial name
- NCT01678963
- Testing
- Squalamine lactate, Vehicle control
- Where
- 20 sites in United States
- Volunteers
- 142 people
- Sponsor
- Ohr Pharmaceutical Inc.
Glaucoma and Ocular Hypertension
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT
The purpose of this study is to investigate the safety and efficacy of up to three concentrations of DE-117 ophthalmic solution (Low Dose, Medium Dose, and High Dose) as monotherapy and as adjunctive therapy (DE-117 ophthalmic…
- Trial name
- NCT01654484
- Testing
- DE-117, 0.0015% tafluprost, DE-117 and 0.0015% tafluprost
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Santen Inc.
Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers, Choroidal Neovascularization
Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops
Study of the safety, tolerability and pharmacokinetic profile of different doses of SYL1801 eye drops in healthy volunteers.
- Trial name
- NCT04782271
- Testing
- SYL18001 sodium Low dose q.d, SYL18001 sodium Middle dose q.d, SYL18001 sodium High dose q.d
- Where
- Spain
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sylentis, S.A.
Dry Eye Disease (DED)
A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye
The objective of this study is to evaluate the safety and efficacy of 0.25% RCI001 Ophthalmic Solution twice a day (BID) and four times a day (QID) compared to placebo (vehicle) in the treatment of the signs and symptoms of dry…
- Trial name
- NCT07068958
- Testing
- 0.25% RCI001 Ophthalmic Solution
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ORA, Inc.
Allergic Conjunctivitis
An Evaluation of the Onset and Duration of Action of AKF-1 Ophthalmic Solution in Treating Acute Allergic Conjunctivitis
The purpose of this study is to evaluate the onset and duration of action of two concentrations of AKF-1 Ophthalmic Solution compared to vehicle in the conjunctival allergen challenge (CAC) model of acute allergic conjunctivitis.
- Trial name
- NCT01561521
- Testing
- AKF-1
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Akorn, Inc.
Dry Eye
Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
Dose response related to efficacy and safety of DE-089 ophthalmic solution are examined in patients with dry eye, using a multicenter, randomized, double-blind, parallel group comparison study, and the optimal concentration is…
- Trial name
- NCT01189032
- Testing
- DE-089 ophthalmic solution
- Where
- Japan
- Volunteers
- 320 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Conjunctivitis, Allergic
A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber
An Exploratory Clinical Trial Evaluating Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects with Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber (EEC)
- Trial name
- NCT03709121
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Dry Eye Disease
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
Efficacy study of ecabet ophthalmic solution in dry eye disease
- Trial name
- NCT00667004
- Testing
- ecabet ophthalmic solution
- Where
- United States
- Volunteers
- 183 people
- Sponsor
- Bausch & Lomb Incorporated
Purulent Bacterial Conjunctivitis
Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.
Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.
- Trial name
- NCT01155999
- Testing
- T1225, Tobramycin
- Where
- France
- Volunteers
- 286 people
- Sponsor
- Laboratoires Thea
Ocular Redness
"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"
This is a multi-center, double-masked, randomized, active-controlled, parallel-group, efficacy and safety study that will enroll 386 participants at up to six clinical sites.
- Trial name
- NCT05360784
- Testing
- Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation, Lumify® (brimonidine tartrate ophthalmic solution 0.025%)
- Where
- 6 sites in United States
- Volunteers
- 380 people
- Sponsor
- Bausch & Lomb Incorporated
Age-Related Macular Degeneration
The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)
The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively treat geographic atrophy associated with age-related macular degeneration.
- Trial name
- OMEGA (NCT00485394)
- Testing
- OT-551
- Where
- 17 sites in United States
- Volunteers
- 198 people
- Sponsor
- Othera Pharmaceuticals
Ocular Redness, Eye Irritation
An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations
The purpose of this study is to assess the safety and efficacy of FID 123320 Ophthalmic Solution compared to Vehicle for relieving redness of the eye due to minor eye irritations in pediatric and adult populations.
- Trial name
- NCT06538662
- Testing
- FID 123320 Ophthalmic Solution, Vehicle
- Where
- 10 sites in United States
- Volunteers
- 283 people
- Sponsor
- Alcon Research
Healthy
Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.
This is a phase I study evaluating safety and tolerability through the incidence of unexpected adverse events and IOP measurement, as well as through the incidence of stinging after its administration, compared to placebo.
- Trial name
- PRO-232 (NCT06352541)
- Testing
- PRO-232
- Where
- Mexico
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Glaucoma, Ocular Hypertension
Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.
- Trial name
- JUPITER (NCT01895972)
- Testing
- Latanoprostene bunod
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Bausch & Lomb Incorporated
Presbyopia
Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients
A multicenter, randomized, double-Blind, crossover, placebo-controlled Phase II clinical Study to evaluate the efficacy and safety of BRIMOCHOL PF and CARBACHOL PF in the treatment of Chinese patients with presbyopia.
- Trial name
- NCT06948357
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Dry Eye Disease (DED)
Cross-linked CMC and Silk Proteins in Eye Disease
Data analyses and revision of the DED symptoms. A novel ophthalmic solution containing cross-linked CMC (CX-CMC) and Silk Proteins (SP) has been made available on the market.
- Trial name
- NCT06605365
- Testing
- CX-HA and CS
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- D&V FARMA srl
Glaucoma, Ocular Hypertension
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
The study purpose is to evaluate the safety of T4090.
- Trial name
- NCT05389267
- Testing
- Kinezodianone R hydrochloride
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Laboratoires Thea
Dry Eye Disease (DED)
Efficacy and Safety of VMX Eye Drops for Dry Eye Disease
This multicenter, randomized, double-blind study evaluates the safety and effectiveness of VMX eye drops in patients with dry eye disease.
- Trial name
- NCT07369375
- Testing
- VMX Eye Drops
- Volunteers
- 76 people
- Sponsor
- VISUfarma SpA
Macular Edema
Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema
To evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution, EGP-437, using the EyeGate® II Drug Delivery System (EGDS) in patients with macular edema (ME)
- Trial name
- NCT02485249
- Testing
- Dexamethasone Phosphate Ophthalmic
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Glaucoma and Ocular Hypertension
Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension
The purpose of this study is to determine the intraocular Pressure (IOP) lowering response and evaluate the safety of brimonidine tartrate 0.025% ophthalmic solution in adult subjects with open angle glaucoma or ocular…
- Trial name
- NCT01687426
- Testing
- Brimonidine Tartrate 0.025%, Vehicle
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Eye Therapies, LLC